Skip to main content

Preventive Health Reviews: Choose Screening by Person, Purpose and Evidence

Use a preventive health review to decide which evidence-based actions are appropriate for an individual, considering age, relevant risk, prior results, current symptoms and informed choice. Screening of an apparently well person, investigation of symptoms and monitoring of known disease are different pathways. An annual invitation should not automatically produce the same blood-test or cancer-screening package for every family member.

By Bractis · Updated · 8 min read

Indian primary-care clinics designing preventive reviews and recall services for adults and families, with responsibility for explaining results and arranging follow-through.

Separate screening, diagnosis and monitoring

A screening offer asks whether an apparently well person belongs to a group for whom a particular test or assessment has a useful evidence-based purpose. A patient with symptoms may instead need diagnostic assessment. A person already receiving care for a condition may need monitoring of that condition.

WHO Europe's screening guide describes potential benefits alongside harms, cost and the need for a complete quality-assured pathway. It is not a list of tests every healthy person should buy. More tests do not automatically mean a better preventive service.

Start the review with the patient's concerns and existing care. A new symptom should not be diverted into a routine 'wellness panel' merely because the appointment was booked under preventive care.

Identify the question each proposed action is meant to answer and what would happen after each possible result. If the clinic cannot explain the next step or arrange it, a test package can create unresolved information rather than useful prevention.

Keep preventive discussion broader than laboratory orders. Relevant counselling, vaccination review or risk-factor assessment may be part of the clinician's plan, without every discussion generating another test.

Source: WHO Europe: Screening programmes, a short guide, 6 February 2020

Use programme guidance with its eligibility and scope intact

India's NP-NCD Operational Guidelines 2023–2030 describe population-based screening for people aged 30 years and above for hypertension, diabetes and cancers of the oral cavity, cervix and breast, within the programme's appropriate pathways. This is important local context, not authority for one identical annual package for everyone over 30.

The relevant individual criteria still matter: the condition being considered, applicable anatomy and history, previous assessment, risk and the method recommended by the responsible clinician. A broad age label should not substitute for these decisions.

The programme connects screening with referral, treatment and follow-up. A private clinic drawing on that context should likewise plan what happens after a finding, rather than treat specimen collection or a camp attendance count as the endpoint.

Record which guidance and version supports an offer and which parts of the patient's history remain uncertain. If outside screening was performed, obtain useful details before repeating it solely because the clinic's own chart is empty.

An invitation can be annual for administrative convenience while individual actions have different clinically appropriate intervals. Keep the review date, each test's due basis and any diagnostic referral separate.

Source: MoHFW: NP-NCD Operational Guidelines 2023–2030, hosted by NHM Mizoram

Make the reason for each offer inspectable

Use a short decision record during the clinical review. It should capture the question, relevant eligibility, existing evidence, benefits and limitations discussed, the person's decision and the next owner.

Do not treat a normal previous result as permanent clearance, or an absent record as proof that a test was never done. Preserve the date and source, then let the clinician decide whether the information is sufficient.

Explain possible consequences in plain language. A positive screening result may need further assessment; a negative result does not rule out every disease or cancel new symptoms. Avoid language such as 'complete cancer clearance'.

Where several tests are offered, explain them individually enough for a meaningful choice. A preselected package consent box can hide a test the patient does not understand or want.

The table is an original review framework, not a screening eligibility algorithm.

On a narrow screen, scroll the table horizontally to read all columns.

Questions to answer before adding a preventive action
DecisionWhat to recordReason it matters
PurposeScreening, symptom investigation, known-disease monitoring or another defined actionPrevents a single annual-panel label from hiding different care pathways
EligibilityRelevant individual criteria and guidance usedAge alone may not settle the choice
Previous evidenceActual date, method, result/source and follow-up already arrangedAvoids unnecessary duplication and false reassurance
Benefits and limitsPlain-language discussion of useful outcomes and possible harmsSupports informed choice rather than fear-based uptake
Patient decisionAgreed, declined, deferred or needing further discussionA declined offer is not a positive test or failed treatment
Result pathwayReviewer, communication and referral/confirmation arrangementA test result needs an accountable next step

Report the pathway without exaggerating uptake

Consider an original fictional group of 40 people invited to an individual preventive review. Twenty-eight agree, eight decline and four have an unknown contact outcome. Those categories total 40; unknown contact is not refusal.

After the 28 reviews, 20 people each have one agreed screening action due, five have no additional screening action due under their reviewed plans, and three need diagnostic assessment of symptoms. These are 28 distinct review outcomes.

Suppose 15 of the 20 agreed screening actions are completed with their defined result-review evidence, leaving five open. Completion is 75% of agreed due actions. It is 37.5% of all 40 invitations, a different measure with a different denominator.

The five people with no action due should not be sent unnecessary tests to improve uptake. The three symptomatic people need the appropriate diagnostic pathway and should not be counted as screening positives merely because they were referred.

The eight people declining review may still use the clinic for other care. Record their choice and contact preferences without portraying it as loss of patient loyalty. A preventive service should support informed decisions, not maximise tests per invitation.

Coordinate the family visit while preserving individual decisions

A family may want a convenient shared appointment day, but each person needs an individual record, discussion and decision. One payer or household organiser does not automatically have permission to see everyone's results.

Offer appropriate privacy and language assistance. Sensitive history may not be disclosed in front of a spouse, parent or employer. Do not make a public reception questionnaire the only route to an individual assessment.

Agree how results will be reviewed and communicated, including outside laboratory reports. A PDF sent to the patient does not establish clinical interpretation or understanding of the next step.

If further assessment is needed, identify the receiving service and a person responsible for tracking the handover. A referral issued but never arranged remains a different outcome from a completed diagnostic decision.

Review unresolved results before inviting another batch. The capacity to explain and act on findings is part of the service; increasing invitations without that capacity can increase unfinished care.

Forty invitations lead to several appropriate outcomes

The fictional cohort has 28 agreed reviews, eight declines and four unknown contacts. The reviews identify 20 agreed screening actions, five people with no additional action due and three diagnostic assessments. Fifteen of twenty screening actions are completed: 75% of that defined group, not proof that everyone invited benefited.

Build an individual prevention plan

Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.

Purpose
Separate screening from diagnostic assessment and monitoring of known disease.
Individual basis
Record relevant eligibility, prior evidence and guidance instead of applying one family package.
Choice and access
Document the person's decision and practical arrangements without pressure.
Result ownership
Assign review, communication and further assessment before ordering or offering a test.

Questions doctors ask

Does an annual health review require annual blood tests for everyone?

No. The review should determine appropriate individual actions from evidence, history and current circumstances. An invitation frequency does not establish the need or interval for every test.

Is testing a person with symptoms the same as screening?

Not generally. Symptoms may require diagnostic assessment, while screening usually concerns an apparently well population meeting relevant criteria. Preserve the actual clinical purpose.

Does NP-NCD make one test package appropriate for everyone over 30?

No. Its population-screening context includes defined conditions and pathways. The individual action still needs appropriate eligibility, method, clinical judgement and follow-through.

Can a normal screening result provide complete health clearance?

No. Every test has scope and limitations. A normal result does not exclude every condition or remove the need to assess new symptoms.

Can all family results be sent to the person paying the bill?

Do not assume that. Establish each person's permitted recipient and disclosure arrangement, separate from payment or booking coordination.

Sources and scope

Updated on . Original preventive-service planning with Indian programme context and WHO screening principles. It does not prescribe a universal test panel, screening interval or eligibility decision for an individual. No independent clinical or legal review is claimed.

Try the workflow
with Bractis.

Build the fictional 40-person review cohort with agreed screening, no-action-due, diagnostic and declined outcomes. Show individual permission, result ownership and distinct denominators.

Request a clinic demo